aTyr Pharma Launches Phase III Trial for Efzofitimod in Pulmonary Sarcoidosis Treatment

aTyr Pharma (ATYR) is set to initiate a new Phase III clinical trial for its drug efzofitimod, specifically aimed at treating pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration (FDA). The trial follows a Type C meeting held in mid-April, where the FDA underscored the significance of evaluating forced vital capacity (FVC) and the King’s Sarcoidosis Questionnaire (KSQ) lung score as critical endpoints.

New Phase III Trial Targets Pulmonary Sarcoidosis

Although a previous Phase III study, known as EFZO-FIT, did not meet its primary endpoint concerning steroid reduction, it showcased a durable benefit in quality-of-life measures among patients. Dr. Sanjay Shukla, President and CEO of aTyr, expresses optimism about the new trial, which will focus on patients with restrictive lung disease. The plan includes submitting a protocol to the FDA next month, marking a pivotal step in their clinical development journey.

Trial Design Aims to Enhance Efficacy

The global, randomized, double-blind, placebo-controlled trial aims to enroll around 372 participants receiving stable doses of corticosteroids. The primary endpoint will assess changes in FVC at week 48, with the KSQ lung score serving as a key secondary endpoint. The trial proposes an adjustment in dosing frequency from monthly to tri-weekly, cultivating increased drug exposure while prioritizing patient safety.

Potential Impact on Respiratory Treatment

This trial represents a significant opportunity for aTyr to expand its therapeutic reach and validate its research strategy in addressing a complex respiratory condition. If successful, the findings could not only enhance treatment options for patients with pulmonary sarcoidosis but also strengthen aTyr's position in the biotech landscape.